- The Little Clinic adds new insurance provider to accepted plans
- Gallup: Take Care Clinics top in customer service
- Bartell to cease filling Medicaid prescriptions at 15 locations
- With health reform outlook dimmed, pharmacy can’t abandon its agenda
- FDA's new video addresses fracture risk when using PPIs
PITTSBURGH The Food and Drug Administration has approved a Mylan generic drug for Parkinson’s disease, Mylan said Thursday.
The drug maker announced the approval of pramipexole dihydrochloride tablets in the 0.125-mg, 0.25-mg, 0.5-mg, 1-mg and 1.5-mg strengths. The drug is a generic version of Boehringer Ingelheim’s Mirapex.
Various versions of the drug had sales of $536 million during the 12-month period ended in June, according to IMS Health. Mylan has had approval of a 0.75-mg formulation of the drug since April, and plans to immediately begin shipping the newly approved strengths.